Key Takeaways
- Nanobodies from llamas and camels could treat Alzheimer’s with fewer side effects
- These tiny proteins are 1/10th the size of conventional antibodies
- They can cross the blood-brain barrier more effectively than current treatments
- Human clinical trials still require further safety and delivery optimization
Protein molecules from llama and camel blood show promise for treating Alzheimer’s disease and other brain disorders with reduced side effects, according to new research. These “nanobodies” could revolutionize neurological treatment by overcoming limitations of current antibody therapies.
What Are Nanobodies?
Nanobodies are a specialized form of antibodies first discovered in the 1990s in camelids – the animal family including camels, llamas, and alpacas. At just one-tenth the size of conventional antibodies, they represent the smallest known functional antibody fragments.
Unlike standard cancer treatments that rely on antibodies, current therapies struggle with brain disorders because antibody molecules cannot effectively cross the blood-brain barrier. Nanobodies’ compact size allows them to penetrate this protective barrier more efficiently.
“Camelid nanobodies open a new era of biologic therapies for brain disorders and revolutionise our thinking about therapeutics,” said Philippe Rondard of Centre National de la Recherche Scientifique (CNRS) in France.
“We believe they can form a new class of drugs between conventional antibodies and small molecules,” said Dr Rondard, an author of the new study published in the journal Trends in Pharmacological Sciences.
Proven Benefits and Advantages
Previous research has demonstrated nanobodies’ potential, showing they can restore behavioral deficits in mice with schizophrenia. Their unique properties offer multiple advantages over conventional treatments.
“These are highly soluble small proteins that can enter the brain passively,” said Pierre-André Lafon from CNRS.
“By contrast, small-molecule drugs that are designed to cross the blood-brain barrier are hydrophobic in nature, which limits their bioavailability, increases the risk of off-target binding, and is linked to side effects,” explained Dr Lafon, another author of the study.
Scientists note that nanobodies are easier to produce, purify, and engineer compared to conventional antibodies. They can be precisely fine-tuned to target specific conditions, potentially creating more effective treatments for and other neurological disorders.
Road to Human Trials
Despite their promise, researchers emphasize that several challenges must be addressed before nanobodies can advance to human clinical trials. Key hurdles include optimizing delivery methods and ensuring complete safety.
“Regarding the nanobodies themselves, it is also necessary to evaluate their stability, confirm their proper folding, and ensure the absence of aggregation,” said Dr Rondard.
“It will be necessary to obtain clinical-grade nanobodies and stable formulations that maintain activity during long-term storage and transport,” he said.
The research represents a significant step toward developing new that could benefit millions affected by brain disorders worldwide.
